Ashok Rakhit

2.7k total citations
65 papers, 2.2k citations indexed

About

Ashok Rakhit is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ashok Rakhit has authored 65 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Ashok Rakhit's work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (14 papers) and Pharmacogenetics and Drug Metabolism (12 papers). Ashok Rakhit is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (14 papers) and Pharmacogenetics and Drug Metabolism (12 papers). Ashok Rakhit collaborates with scholars based in Switzerland, United States and United Kingdom. Ashok Rakhit's co-authors include Marta Hamilton, Bert L. Lum, Scott Fettner, Robert J. Motzer, Michael Pantze, Steve Eppler, R Nadeau, Ronald M. Bukowski, Jie Ling and Myriam Riek and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Clinical Cancer Research.

In The Last Decade

Ashok Rakhit

64 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ashok Rakhit Switzerland 25 981 617 518 444 181 65 2.2k
Dona Alberti United States 30 1.0k 1.1× 419 0.7× 1.4k 2.6× 317 0.7× 77 0.4× 90 2.8k
Craig D. Wegner United States 24 703 0.7× 545 0.9× 857 1.7× 1.1k 2.5× 83 0.5× 54 3.4k
Amarnath Sharma United States 27 994 1.0× 248 0.4× 893 1.7× 605 1.4× 186 1.0× 62 2.8k
Shigemi Matsumoto Japan 26 1.6k 1.7× 636 1.0× 866 1.7× 264 0.6× 95 0.5× 136 3.2k
Gregory D. Ayers United States 28 792 0.8× 317 0.5× 961 1.9× 273 0.6× 123 0.7× 55 2.7k
Stacy S. Shord United States 28 1.0k 1.1× 265 0.4× 714 1.4× 274 0.6× 458 2.5× 69 2.7k
John J. Grygiel Australia 25 494 0.5× 958 1.6× 893 1.7× 162 0.4× 218 1.2× 49 2.4k
Clara Chen United States 24 832 0.8× 401 0.6× 604 1.2× 504 1.1× 58 0.3× 101 2.6k
Sukyung Woo United States 25 460 0.5× 377 0.6× 1.0k 2.0× 252 0.6× 118 0.7× 63 2.2k
Susan L. Kelley United States 17 888 0.9× 281 0.5× 1.3k 2.5× 642 1.4× 56 0.3× 26 3.4k

Countries citing papers authored by Ashok Rakhit

Since Specialization
Citations

This map shows the geographic impact of Ashok Rakhit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashok Rakhit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashok Rakhit more than expected).

Fields of papers citing papers by Ashok Rakhit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashok Rakhit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashok Rakhit. The network helps show where Ashok Rakhit may publish in the future.

Co-authorship network of co-authors of Ashok Rakhit

This figure shows the co-authorship network connecting the top 25 collaborators of Ashok Rakhit. A scholar is included among the top collaborators of Ashok Rakhit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashok Rakhit. Ashok Rakhit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Girgis, Ragy R., Mark Slifstein, Deepak Cyril D’Souza, et al.. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology. 233(19-20). 3503–3512. 97 indexed citations
2.
Hamilton, Marta, Julie Wolf, Daniel W. Drolet, et al.. (2014). The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemotherapy and Pharmacology. 73(3). 613–621. 41 indexed citations
3.
Twelves, Chris, José Trigo, Robert H. Jones, et al.. (2008). Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study. European Journal of Cancer. 44(3). 419–426. 37 indexed citations
4.
Cutsem, Eric Van, Chris Verslype, Philip Beale, et al.. (2007). A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Annals of Oncology. 19(2). 332–339. 29 indexed citations
5.
Rakhit, Ashok, Michael Pantze, Scott Fettner, et al.. (2007). The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition. European Journal of Clinical Pharmacology. 64(1). 31–41. 108 indexed citations
6.
Ling, Jie, Kim A. Johnson, Zhuang Miao, et al.. (2005). METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS. Drug Metabolism and Disposition. 34(3). 420–426. 187 indexed citations
7.
Motzer, Robert J., Ashok Rakhit, John F. Thompson, et al.. (2002). Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma. Annals of Oncology. 13(11). 1799–1805. 38 indexed citations
8.
Motzer, Robert J., Ashok Rakhit, John A. Thompson, et al.. (2001). Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell Carcinoma. Journal of Interferon & Cytokine Research. 21(4). 257–263. 83 indexed citations
9.
Leyland‐Jones, Brian, Andrew Arnold, Karen Gelmon, et al.. (2001). Pharmacologic insights into the future of trastuzumab. Annals of Oncology. 12. S43–S47. 16 indexed citations
10.
11.
Zeuzem, Stefan, U. Hopf, Vicente Carréño, et al.. (1999). A Phase I/Ii Study of Recombinant Human Interleukin–12 in Patients With Chronic Hepatitis C. Hepatology. 29(4). 1280–1287. 41 indexed citations
12.
Chen, Chao, Bradford K. Jensen, Goutam C. Mistry, et al.. (1997). Negligible Systemic Absorption of Topical Isotretinoin Cream: Implications for Teratogenicity. The Journal of Clinical Pharmacology. 37(4). 279–284. 18 indexed citations
13.
Chen, Chao, Goutam C. Mistry, Bradford K. Jensen, et al.. (1996). Pharmacokinetics of Retinoids in Women after Meal Consumption or Vitamin A Supplementation. The Journal of Clinical Pharmacology. 36(9). 799–808. 14 indexed citations
14.
Zhi, Jianguo, Angela T. Melia, Roberto Guerciolini, et al.. (1996). The Effect of Orlistat on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers. The Journal of Clinical Pharmacology. 36(7). 659–666. 36 indexed citations
15.
Rakhit, Ashok, et al.. (1992). Effect of Chronic Hypertension on the Blood–Brain Barrier Permeability of Libenzapril. Pharmaceutical Research. 9(2). 236–243. 12 indexed citations
16.
Stephen, S., Louis L. Martin, Ashok Rakhit, et al.. (1992). Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. Kidney International. 41(1). 199–205. 37 indexed citations
17.
Singh, K. Chandramani, et al.. (1991). Determination of in vivo hepatic extraction ratio from in vitro metabolism by rat hepatocytes.. Drug Metabolism and Disposition. 19(5). 990–996. 10 indexed citations
18.
Martin, Louis L., et al.. (1991). Pharmacokinetics of CGS 12970 and inihibition of thromboxane synthesis after oral administration in healthy adults. Clinical Pharmacology & Therapeutics. 49(4). 433–441. 3 indexed citations
19.
Rakhit, Ashok, et al.. (1988). Effect of renal impairment on disposition of pentopril and its active metabolite. Clinical Pharmacology & Therapeutics. 44(1). 39–48. 11 indexed citations
20.
Rakhit, Ashok, et al.. (1988). Pharmacokinetic disposition of the novel atypical anxiolytic CGS 9896 in the cynomolgus monkey. Psychopharmacology. 94(3). 332–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dona Alberti Breakdown of academic impact, for papers by Craig D. Wegner Breakdown of academic impact, for papers by Amarnath Sharma Breakdown of academic impact, for papers by Shigemi Matsumoto Breakdown of academic impact, for papers by Gregory D. Ayers Breakdown of academic impact, for papers by Stacy S. Shord Breakdown of academic impact, for papers by John J. Grygiel Breakdown of academic impact, for papers by Clara Chen Breakdown of academic impact, for papers by Sukyung Woo Breakdown of academic impact, for papers by Susan L. Kelley
Rankless by CCL
2026